Author:
Liu Fei Fei,Bartlett Meaghan,Craigie Samantha
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference80 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
2. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
3. Gandhi S, Kallab AM, Hernandez-Ilizaliturri FJ. Diffuse large B-cell lymphoma (DLBCL) guidelines. 18 Nov 2022. https://emedicine.medscape.com/article/202969-guidelines. Accessed 25 Oct 2021.
4. Tilly H, Gomes da Silva M, Vitolo U, et al., on behalf of the ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v116–v25.
5. Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–73.